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1. Introduction 
HIV can cause a wide range of neurocognitive complications recently grouped under the 
name of HAND (HIV associated neurocognitive disorders). Depending on the degree of the 
impairment, there are three categories, progressing in disabilities from asymptomatic 
neurocognitive impairment (ANI) to HIV associated mild neurocognitive impairment 
(MND) and to HIV associated dementia (HAD)[1]. 
The introduction of HAART (highly active antiretroviral therapy) has led to a marked 
decrease in the incidence of HAND. But also the spectrum of HAND has changed in the 
HAART era; it seemed that minor cognitive impairment slightly increased. HAND consists 
of a triad of cognitive, behavioral and motor dysfunctions. With the exception of dementia, 
the symptoms are generally mild but can impact the quality of life and treatment adherence. 
Diagnosis of HAND is based on a combination of careful history and neurological 
examination, neuropsychological testing, neuroimaging (especially magnetic resonance: 
MRI) and cerebrospinal fluid (CSF) analyses. The last two have a crucial role in 
differentiating from other etiologies. The differential diagnosis is quite broad in HIV patient 
with neurological impairment including HIV- related causes and also metabolic 
disturbances, substance abuse and psychiatric disorders. 
Initiation of HAART with a good CNS penetration is the most effective mean of treating 
cognitive impairment.[2] 
2. Epidemiology  
HIV-encephalitis (HIVE) is the most frequent neurologic disorder of the brain in HIV-1 
infection and is the principal cause of HAND. Neurocognitive impairments in overall HIV 
population appear to be nearly 50% [1], varying considerably by the region, due to the tests 
used for detection, HIV infection stage and comorbidities, virus subtype and treatment 
schedules.  
The large majority of HIV-associated neurocognitive disorders (HAND) are asymptomatic 
(ANI) or mild (MND), but around 5% are severe, representing an AIDS-related illness: HIV-
associated dementia (HAD). [3,4]  
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Paradoxically, HAART introduction didn’t decrease the occurrence of HAND, but there was 
a shift from severe to moderate and mild forms [5]. Causes of continuing high rates of 
HAND despite HAART, have multiple possible explanations:  
- the presence of irreversible brain injury prior to initiating ART;  
- the possible neurotoxicity of some antiretroviral drugs;  
- the persistence of minimal HIV replication in CNS and 
- the effect of chronic immune activation, condition that lead to metabolic disorders and 
vascular degeneration, inclusive of CNS tissue.[6] 
Risk factors for developing HAND included 
- host factors: low educational status, older age, genetic predisposition, metabolic 
disorders, coinfection with hepatitis C virus and iv drug abuse.  
- viral factors: virus subtype (subtypes B, C and D more related to HAND than subtype 
A; subtype F also associated with high prevalence of HAND) [1,7]  
- relation host-virus: AIDS stage and presence of chronic immune activation - measured 
by different serum markers such as TNF-alpha and monocyte chemo-attractant protein 
1 (MCP-1), hsCRP, IL6 and soluble CD14 - which leads to metabolic disorders and 
accelerated senescence; low nadir of CD4 T cell counts [8, 9]; HIV-DNA load in circulant 
macrophages and higher CSF viral load compared to serum viral load.[10,11] 
Although HIV penetrates CNS early (during the acute HIV infection), the onset of HAND is 
delayed for years, superposing with moderate and advanced immune-suppression stages 
[12, 5]. It emerges gradually, in weeks or months.  
There are no conclusive data regarding the HAND outcome: there is a variable degree of 
reversibility for ANI and MND, unlike typical neurodegenerative syndromes and MND 
doesn’t progress necessarily to HAD.[1]. Although it is considered to be a treatable 
condition, HAND is associated with a shortened survival [13].  
3. Pathogenesis of HIV encephalitis 
HIV-encephalitis (HIVE) represents the mainly HAND substrate.  
HIV enters the central nervous system early during the infection [12,5], transported by CD4 
T lymphocytes and monocytes, that cross the blood-brain barrier (BBB). The infected 
monocytes become perivascular macrophages in nervous tissue. Then, HIV infects local 
macrophages (microglia). Perivascular macrophages and microglia fused together, forming 
multinucleated giant cells (MGCs). MGCs replicate the virus (serving as HIV-reservoir) and 
express neurotoxic molecules: viral (gp-120 and tat protein) and cellular [14]. These 
neurotoxins have at least two properties:  
- they activate astrocytes, which in turn release cytokines and increase BBB permeability, 
promoting migration of more HIV-infected cells from blood to brain.  
- they damage the neurons, with demyelination and neuronal loss. 
Therefore, the picture of local histopathology in HIVE shows inflammatory changes and 
neuronal destructions: perivascular macrophages accumulation, reactive gliosis with 
microglial nodules and MGCs formation and focal neuronal necrosis with demyelination 
and neuroatrophy [15,1]. 
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Macroscopically, in HIVE, there is global white matter pallor, a reduction in nervous 
substance thickness, especially in deep grey matter structures and in subcortical frontal 
white matter. Mostly affected are basal ganglia (especially caudate nucleus), corpus 
callosum and hippocampus, which correlate well with clinical cognitive and behavioral 
syndromes – but in a lesser extent with motor manifestations [1]  
HIV proved to damage the neurons directly, via viral neurotoxins and indirectly, via 
immunologic pathways. The lasts consist in local changes (already mentioned cellular 
neurotoxins and BBB deterioration) and systemic changes, which means chronic immune 
activation. 
The chronic immune activation can be done by any persistent infectious or noninfectious 
inflammation. The repercussion is an accelerated immune-mediated global vascular 
senescence (endothelial dysfunction with subsequent atherosclerosis) which has as 
consequences many metabolic disorders[16], including neuro-degeneration (subclinical 
atherosclerotic disease of the brain vessels) 
In HIV infection, chronic immune activation takes place even in HIV-treated patients, with a 
good control of the plasma viral load, but with a poor control of viral sanctuary (reservoirs). 
It is demonstrated that despite plasma level suppression, HIV could continue to replicate in 
brain tissues with a rate of 3-10% [1]. This replication (as low as 2 copies/ml) is capable to 
maintain a persistent immune activation [8] with its consequences. The HIV presence/ 
persistence in the brain in the HAART era has a series of explanations:  
- incomplete suppression: the virus can not be totally suppressed in the brain tissues 
because of the poor penetration of antiretrovirals through BBB, thus too low drug’s 
concentrations achieve there allowing the development of different HIV (resistant) 
cvasispecies in CNS. [8].  
- viral afflux from peripheral reservoirs: there could exists a permanent traffic of the 
mononuclear infected cells (with pro-viral DNA: HIV-DNA) from peripheral reservoirs 
(bone marrow) to the brain. Even in patients with undetectable plasma viral load, we 
can find HIV-DNA in circulating monocytes, with the same viral signature as in the 
bone marrow and in the deep brain structures.  
Other factors that may contribute to neurocognitive disorders in HIV patients with HIVE in 
HAART era are: 
- the medication per se (antiretrovirals or miscellanea), which can have neurotoxic effects 
- aging - there is an accelerated neuro-degeneration in older HIV subjects, which has 
similarities with neurodegenerative syndromes, with abnormal accumulation of beta-
amyloid apolipoproteinE4, tau protein and synuclein[1,5] 
- hepatitis C virus coinfection: both viruses invade SNC and cause synergic neurotoxic 
effects.  
- iv drug abuse contribute to neuro-degeneration 
A particular situation in HIV treated patients is IRIS (immune reconstitution syndrome). A 
severe HIVE development can be observed in patients receiving HAART, with a low basal 
CD4 T lymphocytes count and high initial HIV-RNA level, despite the good suppression 
obtained under treatment. Histo-pathologically numerous CD8-positive lymphocytes were 
found close to the neurons, in the perivascular areas and in the parenchyma. This condition 
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may be interpreted as an immune reconstitution phenomenon directed against HIV itself [17], 
leading to an extensive white matter destruction, with vacuolar leucoencephalopathy [12] 
The neuro-injury in HIVE can be paraclinically appreciated by:  
- biochemical and molecular analysis of plasma and CSF: uncontrolled viral replication 
increases the HAND risk; discordances in viral loads, with higher CSF load represent a 
particular risk; the presence of high levels of neopterin and beta-microglobulin in CSF 
(neuro-degeneration and macrophage/microglial activation markers) even in the 
absence of a CSF viral replication correspond to neuronal impairment; the low number 
of CD4 T lymphocytes in peripheral blood increases the risk of HAND (especially at 
CD4 below 200/mmc)[3]; presence of the chronic immune activation markers in 
peripheral blood is also a predictive factor for HAND, measured by hsCRP, soluble 
CD14, D-dimers, IL6, TNF-alpha and MCP-1; high level of HIV DNA in peripheral 
monocytes correlates well with HAND.  
- histological, biochemical and molecular analysis of the nervous parenchima: there is 
reported HIV presence in brain tissue more frequently than in CSF [18,1-16], suggesting 
that CSF levels may underestimate HIV replication in brain tissue.  
- imaging-based methods which can appreciate the nervous tissue injuries in HIVE 
At present, the main goal of treatment is the effective suppression of the HIV from reservoirs, 
that can disrupt the vicious circle of chronic immune activation and reverse (partially) HIVE. 
4. HIV-associated neurocognitive disorders – Nomenclature and staging  
In 1991 the American Academy of Neurology AIDS Task Force developed a consensus 
nomenclature and case definition for HIV associated dementia (HAD) complex. Several 
terms are still used interchangeably, including AIDS dementia complex, HIV 
encephalopathy, HIV subacute encephalitis, and HAD. The severity of dementia in the 
consensus nomenclature (mild, moderate, and severe) reflects functional deficits that affect 
the activities of daily living.(19) 
A milder form of cognitive impairment, HIV-1-associated minor cognitive/motor disorder 
(MCMD), was also introduced in 1996; however, it was not determined whether this 
represented an intermediate step in the progression to dementia. Subsequent research has 
shown that MCMD is a risk factor for HAD [20]. 
Since the introduction of HAART in 1996, the incidence of moderate or severe dementia fell 
from about 7% in 1989 to only 1% in 2000, and the severity of neurological disease appears 
to have been attenuated (21). Despite this remarkable effect on incidence rates, the 
prevalence of HIV Associated Neurocognitive Disorders (HAND) continues at very high 
rates. In response to the changes, in 2007 the National Institutes of Health created a working 
group to critically review the adequacy and utility of current definitions and diagnostic 
criteria (22). The report provides a new nosology (Table 1) witch distinguishes among 
patients with subclinical dysfunctions categorized as suffering asymptomatic 
neurocognitive impairments (ANI) , patients with greater cognitive decline that have mild 
adverse effects on daily living activities categorized as HIV-associated mild neurocognitive 
disorder (MND) and patients with significant functional impairment who can be 
categorized as having HIV – associated dementia (HAD). An algorithm is proposed to assist 
in standardized diagnostic classification of HAND. The clinical algorithms give guidelines 
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for decision making regarding: (1) cognitive impairment, (2) functional decline, (3) factoring 
in comorbidities, and alternative approaches when full neurodiagnostic assessment 
capabilities are not available (22). 
HIV-associated asymptomatic neurocognitive impairment (ANI) 
Acquired impairment in two or more cognitive domains, with evidence of performance 
>1.0 SD below the mean for age- and education-appropriate norms on standardized 
neuropsychological tests 
Cognitive impairment does not interfere with everyday functioning 
Cognitive impairment does not meet the criteria for delirium or dementia 
No evidence of another preexisting cause for the ANI 
If prior ANI existed, but no longer does, a diagnosis of ANI in remission is made 
Diagnosis deferred for patients with major depression or substance abuse on examination 
HIV-associated mild neurocognitive disorder (MND) 
Acquired impairment in two or more cognitive domains, with evidence of performance 
>1.0 SD below the mean for age- and education-appropriate norms on standardized 
neuropsychological tests 
Typically, impairment staging corresponds to an MSK scale stage of 0.5 to l 
The cognitive impairment produces at least mild interference in daily functioning (at least 
one of the following): (a) self-report of reduced mental acuity, inefficiency in work, 
homemaking, or social functioning; (b) observation by knowledgeable others that the 
individual had undergone at least mild decline in mental acuity with resultant 
inefficiency in work, homemaking, or social functioning 
The cognitive impairment does not meet the criteria for delirium or dementia 
No evidence of another preexisting cause for the MND 
Remission and comorbid psychiatric disturbance criteria similar to that for ANI 
HIV-associated dementia (HAD) 
Marked acquired impairment in at least two cognitive domains. Typically impairments 
involve multiple domains, especially in learning of new information, slowed information 
processing, and defective attention/concentration 
The impairments must be >2 SD below average on neuropsychological testing 
Correspond to an MSK scale stage of 2.0 or greater 
The cognitive impairment markedly interferes with daily functioning 
The impairments do not meet the criteria for delirium 
No evidence of another preexisting cause for dementia, such as CNS infection, neoplasm, 
etc.,or severe substance abuse compatible with CNS disorder 
Remission and comorbid psychiatric disturbance criteria similar to that for ANI and 
MND. 
However, if dementia persists after one month on remission of major depression, a 
reassessment should be conducted to reassess for dementia 
Table 1. Nosology of HIV-associated neurocognitive impairment (22). 
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5. Clinical manifestations 
Neurocognitive impairment in people with HIV is characterized by a triad of cognitive, 
psychological, and motor dysfunctions. Symptoms may include any combination of the 
following: distractibility, poor concentration or attention, memory problems on short-term 
or long-term, impaired problem-solving or calculation ability, reduced ability to plan ahead, 
difficulty learning new things, problems with speech and language comprehension, 
abnormal visual perception, psychomotor slowness, poor balance, clumsiness, changes in 
mood (e.g., apathy, depression), social withdrawal, altered behaviour. 
Specific neurological manifestations depend on which parts of the brain are affected. 
Impairment can range from so mild that it is not apparent without specialized testing, to so 
severe that it prevents independent living. 
HIV-associated dementia (HAD) is diagnosed when there is evidence of marked declines in 
function in at least two separate cognitive domains, along with evidence of functional 
deterioration affecting activities of daily living (ADL) and self care. By definition, there must 
be evidence of significant declines from premorbid abilities. 
The early described cases of HAD presented clinical features different from “classic” 
dementias such as Alzheimer’s disease and other cortical degenerative diseases (23). HAD is 
considered a “subcortical” type of dementia”, the neuropsychological profile involving : 
executive functions (ability of planning, decision-making, mental flexibility), concentration 
and complex attention ( sustained attention, divided attention, selective attention, 
processing speed), verbal memory, learning and memory recall (24,25). Cortical dementia is 
more likely to involve memory loss, language comprehension, visual- spatial dysfunction 
and deficient conceptual abilities. Most patients with HAD do not present primary amnestic 
disturbances. Impairments of memory and learning are different from those seen in 
Alzheimer’s disease: usually is retained the ability to store new memory but the efficiency 
for learning is diminished and the recognition memory is better preserved than recall 
memory, suggesting that the hippocampus is less affected.  
Some patients with HAD may experience severe memory impairments or cortical symptoms 
that are virtually impossible to distinguish from Alzheimer’s disease and related dementia. 
The cognitive domains most commonly affected are those of attention and executive 
functions (23, 26, 27). Impaired reaction time and reduced processing speed determining 
cognitive slowing reflects the effects of HIV on subcortical white and the basal ganglia, most 
notably the caudate nucleus (the caudate has been shown to be particularly vulnerable to 
HIV) (28, 29,30). Primary language functions are not very affected in HAD, severe aphasia 
being rare present but verbal fluency is frequently impaired as an expression of executive 
dysfunction (31). 
Patients with HAD frequently show impaired motor abilities even when other cognitive 
functions are relatively intact (26). They can present: psychomotor slowing, poor 
coordination, tremors, impaired fine motor skills (egg, handwriting, buttoning etc). The 
presence of motor problems along with other cognitive problems is one of the key factors 
that distinguished AIDS–dementia from Alzheimer’s disease and related dementias (32). 
Behavioral changes include irritability, apathy, reduced social contact, decreased libido, and 
altered sleeping patterns. Mild to moderate depressive symptoms may precede the onset of 
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HAD (33); however, significant depression may confound the diagnosis of HAD and needs 
to be considered along with HAD since depressive symptoms can be ameliorated with both 
pharmacological and nonpharmacological intervention. 
Patients with mild to moderate cognitive impairment often have a normal neurological 
exam. Early neurological findings include abnormal pursuit and saccadic eye movements 
and reduced rapid alternating and sequential hand movements. Later, patients develop gait 
abnormalities, hyperreflexia (ankle reflexes may be normal or reduced if HIV-associated 
neuropathy coexists) and postural instability. As HAD progresses, ataxia, tremor, 
hypertonia, and frontal release signs appear. 
5.1 Milder neurocognitive disorders (ANI or MCD) 
For milder forms of HAND, difficulties in concentration, attention, and memory may be 
present while the neurologic examination is unremarkable (34). Affected individuals are 
easily distracted, make errors in tasks regularly conducted, lose their train of thought, 
complain of increased fatigue due to effort to organize, plan and making decision, require 
repeated prompting. Activities of daily living may take longer and become more laborious. 
Overall the clinical manifestations are similar to those of HAD but of lesser severity. 
6. Diagnostic workup 
6.1 Biomarkers of HIV- Related Central Nervous System Disease 
CSF analysis is critical in ruling out alternative etiologies. Tests useful for differential 
diagnosis include: opening pressure, culture (particularly fungal and mycobacterium), cell 
count, protein, cryptococcal antigen, VDRL for neurosyphilis and polymerase chain reaction 
testing for toxoplasma, cytomegalovirus, Epstein Barr virus, John Cunningham virus, and 
herpes virus. 
The CSF profile of patients with HAND is often indistinguishable from HIV-infected 
individuals without cognitive impairment. The nonspecific abnormalities may include mild 
elevated total protein and mild mononuclear pleocytosis. Almost all patients with HAD 
have elevated protein levels. A CSF leucocytosis greater than 50 cell/µL is unlikely to be due 
to HIV alone, especially when the CD4 is below 200 cell/ µL (35). A polymorphonuclear 
pleocytosis is unlikely with HAD and raised the possibility of bacterial meningitis or 
cytomegalovirus ventriculitis (36). 
Many biomarkers have been described but the discovery of reliable diagnostic markers has 
been elusive (37). These biomarkers can be divided into those related to pathogenesis and 
those reflecting the state of relevant cells. Recent studies have shown that both markers of 
immune activation (neopterin and beta-2 microglobulin) and neuronal destruction 
(neurofilament light chain) are elevated in HAD (38). 
β-2-microglobulin (light chain of the HLA I expressed on the surface of all nucleated cells 
with the exception of neurons) presents elevated concentrations in CSF in both 
inflammatory and lymphoproliferative conditions (39). CSF β-2-microglobulin correlates 
well with the severity of HAD and the levels decrease with successful treatment of HIV (39). 
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Neopterin (a product of guanosine triphosphate metabolism, mainly produced by activated 
monocytes, macrophages, and microglia) presents high CSF concentrations in patients with 
opportunistic CNS infections as well as HAD. The CSF concentrations correlate with HAD 
severity and decrease with antiretroviral therapy (40). In one study after 2 years of virologic 
suppression, only 55% had normal CSF neopterin levels (41).  
Neurofilament-Light (a major structural element of large myelinated neurons) presents CSF 
levels significantly but nonspecifically raised in HAD and rise with HAART interruption (42, 
43). It seems that levels fall to normal in the majority of patients initiated on HAART (44).  
HIV RNA 
Plasma HIV RNA levels are not specific or sensitive to HAND. In HAART-treated patients, 
an undetectable plasma RNA level seems to occur more often in HAD for reasons that are 
unclear (45). 
CSF HIV RNA is also nonspecific, with elevated levels in HAD, asymptomatic patients and 
those with opportunistic infections (45,46,47). Prior to HAART, higher CSF HIV RNA 
correlated with lower neuropsychological scores in subjects with more advanced disease 
(48). HAD can occur in the absence of an elevated HIV RNA in CSF (49, 50,51). Possible 
explanations for this situation are: residual deficits despite HAART (49); the presence of 
confounding conditions like hepatitis C or substance abuse or autonomous immune 
activation in response to the initial HIV infection (50) .  
6.2 Neuroimaging 
HAD is a diagnostic of exclusion. Computed tomography (CT) and magnetic resonance 
imaging (MRI) studies of the brain can support a diagnosis of HIV encephalopathy (HIVE) 
and rule out HIV-associated opportunistic infections or neoplasm.  
CT scan reveals diffuse cortical atrophy, ventricular enlargement, and hypodensities in 
white matter in later stages. Basal ganglia calcifications are seen in adults but are more 
common in children. Usually computer tomography investigations offer normal results in 
ANI and MND. 
MRI: When the infection becomes clinically symptomatic, the most common MRI findings 
are general atrophy in both cortical and subcortical regions of the brain (52). More 
specifically, these regions include frontal white matter and basal ganglia (53,54), with 
modifications in this area becoming more prominent in most advanced HAND stages. 
Caudate nucleus atrophy is a common finding (54,55,56). Another common imaging finding, 
although not a defining MRI feature of HIVE, is the presence of T2-weighted hyperintenses 
images in white matter of the CNS (white matter signal abnormalities WMSA) (52,57,58). 
These lesions without mass effect can be solitary, diffuse unilateral or large bilateral, and are 
located predominantly in the periventricular white matter and centrum semiovale These 
usually do not enhance after iv contrast administration and are better reveled on FLAIR MR 
sequences. WMSA corresponding loci of demyelization and vacuolation was shown to be 
related to HIV infection (dendrite pruning) (59) but also to vascular risk factors among older 
HIV infected patients (60). MRI findings are often but not always associated with performance 
on cognitive tests and are not always correlated with immunological function (CD4) or disease 
activity (viral load). Structural changes are sensitive to later stage of HAND but do not 
characterize very well the asymptomatic or the milder stages of the HIVE. 
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Fig. 1. HIVE. MRI (T2-w FLAIR) transversal section: symmetric high signals in subcortical 
profound white matter and in periventricular areas (INBI Matei Bals collection, courtesy of 
Dr. M. Mardarescu)  
 
Fig. 2. HIVE. MRI (T2-w) transversal section: symmetric high signals in periventricular 
subcortical white matter, predominantly in parietal posterior areas (INBI Matei Bals 
collection, courtesy of Dr. M. Mardarescu) 
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Fig. 3. HIVE. MRI (T2-w FLAIR) coronal section: symmetric high signals in periventricular 
white matter, predominantly in parietal posterior areas (INBI Matei Bals collection, courtesy 
of Dr. R. Draghicenoiu) 
 
Fig. 4. HIVE. MRI (T2-w FLAIR) coronal section: mild ventriculomegaly with periventricular 
linear hypersignal and high signals in subcortical white matter (INBI Matei Bals collection, 
courtesy of Dr. R. Draghicenoiu) 
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Proton Magnetic Resonance Spectroscopy (MRS) is a functional imaging technique that 
allows measuring a specific set of brain metabolites concentrations noninvasively. The most 
commonly reported neurochemical spectra in the examination of HIV + patients are: N -
acetyl aspartate (NAA) -a marker of neuronal integrity, myo-inositol (mI) a glial cell 
marker, Choline (Cho) a marker of cell turnover and creatine (Cr) a marker of energy 
metabolism. Choline is useful in examining the white matter abnormalities and the 
creatine spectra is often used as a reference peak because the Cr signal is relatively 
constant across subjects. Functional MRI studies are not yet widely available, but they 
may be useful in examining HIV associated CNS abnormalities before neurocognitive 
disorders can be detected by clinical or neuropsychological evaluation. (61). Altered 
metabolic function in HIV infected persons appears early in the course of disease 
progression and is demonstrable by an elevation in Cho, mI and occasionally Cr in frontal 
areas and in the basal ganglia even in the asymptomatic stages (62,63,64). Elevations of 
these metabolites are interpreted to be a marker of inflammation and of glial activation 
and astrocytosis. In more advanced stages of the disease has been observed a decrease of 
NAA, especially in the frontal and subcortical areas of the brain, signaling neuronal injury 
(65, 66,67). The decreased NA/Cr ratio is more important in younger persons, suggesting 
that in older individuals, the metabolic changes seen may be a combination of age and 
HIV infection. There are equivocal evidences of metabolites improvement in HAART-
treated patients but this issue requires further studies. 
Diffusion Magnetic Resonance Imaging (DTI) is a relatively new MRI technique that 
produces images of biological tissues weighted with the local microstructural characteristics 
of water diffusion, which is capable of showing connections between brain regions. 
Researchers have focused on two primary metrics: the mean diffusivity (MD) and fractional 
anisotropy (FA). Several studies suggest that DTI is sensitive in revealing subtle white-
matter abnormalities in the HIV+ cohort. General reductions in FA and increases in MD are 
apparent in multiple white-matter regions, especially in the frontal white matter and the 
corpus calosum, as compared to healthy controls but continued research in this field must 
be done (68,69,70,71). 
Single-photon emission computed tomography (SPECT) may reveal abnormalities in 
cerebral blood flow in frontal, temporal, and parietal areas of the brain, the severity of which 
was shown to be associated with severity of cognitive symptoms (72,73,74). 
PET imaging: Several studies demonstrated hypermetabolism of glucose in the basal 
ganglia, thalamus, temporal and parietal lobes (75,76,77) early in the disease even in the 
asymptomatic stage (75). In more advanced stages of the disease it was observed a 
hypometabolism for cortical and subcortical gray matter (78). The use of a new PET ligand 
[11C]-PK11195 might provide a window into active areas of inflammatory processes in HIV 
infection. PET scanning may also be useful to exclude CNS lymphoma, which shows 
increased uptake, whereas the lesions of HAND do not.  
There are several other MRI imaging modalities that have been used to examine HIV-
associated CNS effects: perfusion MRI, magnetization transfer imaging, and postcontrast 
enhancement imaging but the studies available are limited. 
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6.3 Neuropsychological testing 
The diagnosis of HAND implies exclusion of other causes of cognitive impairment by 
neurological examination and neuroimaging evaluations. Neuropsychological assessment is 
important to quantify and determine the specific pattern of the cognitive abnormality, to 
classify the severity of the deficits (to detect mild, early cognitive abnormalities) and to long 
term follow up.  
The assessment needs to be comprehensive enough to assess abilities of attention, working 
memory, delayed recall, learning, verbal fluency, speed of information processing, 
abstraction/problem solving and motor functions. It is important to use demographically-
corrected norms even for these screening tools (79). 
European AIDS Clinical Society recommended screening for neurocognitive impairment. 
Any HIV-infected person complaining of disturbances in his/her memory (comprehension, 
clarity or speed) should be evaluated extensively, including neurological examination, 
neuropsychological assessment, cerebrospinal exam and imaging of the brain. 
Patients without such symptoms that should be targeted for screening:  
 uncontrolled HIV infection (detectable plasma HIV RNA) 
  use of antiretroviral agents with limited CNS penetration  
 low CD4 nadir (<200 cells/mm³)  
 ongoing depression  
Screening tool  
 International HIV Dementia Scale (IHDS) 
Assessment Methods:  
S Letendre and co proposed a multi-step assessment of a HIV infected person susceptible for 
neurocognitive impairment consisting in: 
Symptom Questionnaire: The Medical Outcomes Study HIV (MOS-HIV) Health Survey (table 
2), The Patient's Assessment of Own Functioning Inventory PAOFI 
Screening Tests: International HIV Dementia Scale, HIV Dementia Scale, Montreal Cognitive 
Assessment 
Brief Neuropsychological Testing: ALLRT Brief Neurocognitive Screen, Grooved Pegboard, 
Action Fluency, Computerized Testing 
Comprehensive Neuropsychological Testing: At least 5 cognitive abilities; At least 2 tests per 
ability 
The most widely accepted neuropsychiatric screening techniques is the International HIV 
Dementia Scale (IHDS), although this scale is not enough sensitive for the assessment of 
early cognitive impairment. The scale consists of 4 subsets that target memory (e.g., recall, 
registration), psychomotor speed, constructional ability, and concentration.  
A patient with a negative screening test may require more in-depth neuropsychological 
testing (80). 
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How much time during the past 4 
weeks..... 
All of 
the 
time 
Most of 
the 
time 
A good 
bit of the 
time 
Some of 
the time
A little 
of the 
time 
None of 
the time 
Did you have difficulty reasoning and 
solving problems, e.g. making plans, 
making decisions, learning new things?
1 2 3 4 5 6 
Did you forget things that happened 
recently, e.g., where you put things, 
appointments? 
1 2 3 4 5 6 
Did you have trouble keeping your 
attention on any activity for long? 
1 2 3 4 5 6 
Did you have difficulty doing activities 
involving concentration and thinking? 
1 2 3 4 5 6 
Knippels, et al. AIDS.2002; 16: 259-267 
Table 2. MOS – HIV Cognitive Functional Status Scale 
Sacktor NC; Wong M; Nakasujja N; Skolasky RL; Selnes OA; Musisi S; Robertson K; 
McArthur JC; Ronald A; Katabira E. AIDS 2005;19(13):1367-74.  
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In advancing disease, tests that explore the following abilities may be helpful: 
 Motor ability : Finger Tapping Test, Grooved Pegboard Test 
 Concentration: Continuous Performance Test, Trail Making Test A and B 
 Processing :Trail Making Test A and B, Choice Reaction Time 
 Memory/learning : Weschler Memory Scale, California Verbal Learning Test 
 Abstraction: Wisconsin Card-Sorting Test 
 Speech/language: Boston Naming Test, Verbal Fluency Test 
In addition to the neuropsychological tests, it is also recommended to briefly assess the level 
of depressive complains using a validated psychiatric scale. The assessment should be 
complemented by an examination of activities of daily living (81) as this assessment serves 
to ascertain the presence of dementia versus milder stages of HAND (22,82).  
Assessment of substance use history is of particular importance. The type of drugs, length of 
use, mode of use, and dosage should be recorded as they help to interpret the current level 
of neurocognitive abilities. 
A brief assessment of medication adherence is recommended because it has been shown to 
be associated with severity of cognitive impairment in HIV-infection (83). 
7. Differential diagnosis 
Due to similar symptoms and signs, the differential diagnosis of HIV encephalopathy 
includes opportunistic infections as well as neoplastic etiology and encephalopathy due to 
reversible causes. We should also take into consideration HAART neurotoxicity and IRIS. 
7.1 Opportunistic infections 
Progressive multifocal leucoencephalopathy (PML) is the most common infiltrative brain 
lesion observed in patients with AIDS and is caused by a reactivation of the dormant JC 
virus,a DNA polyomavirus.The incidence of PML has not decreased after HAART 
introduction, being around 1-10% of AIDS patients.(84,85). The viral tropism for 
oligodendrocytes results in a progressive demyelinating disease and the symptoms depends 
on the afflicted areas. The common complaints are limb weakness (50% of cases), 
disturbance of speech, cognitive abnormalities(25 %), gait disorder (30%), seizures (10%) 
and visual impairments. The definitive diagnosis of PML is made by brain biopsy but due to 
its invasive character and occasional morbidity, it was replaced by newer techniques such as 
PCR for JC virus in the CSF and radiologic imaging. 
PCR assays for the detection of JC virus DNA in the CSF are highly sensitive and specific 
(86) and could be used as a prognostic tool because it was observed that higher levels of JC 
in the CSF were correlated with lower survival rates. (87,88). 
MRI is the modality of choice due to its higher sensitivity of lesion detection and superior 
contrast resolution compared to CT. Commonly, both PML and HIV encephalopathy 
displays nonenhancing lesions in the subcortical white matter, with little or no mass effect 
and hyperintense on T2-weighted and FLAIR magnetic resonance(89). But PML lesions are 
usually hypointense on T1-weighted images and become more hypointense as the disease 
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progresses (89 ).Typical imaging findings are patchy areas, often bilateral and asymmetric, 
located predominantly just bellow the cortical ribbon, involving the arcuate ( U) fibers and 
sometimes seen in brainstem and cerebellum (90). 
Magnetization transfer (MT) imaging is a new type of MR imaging which appears to be 
much more sensitive than standard MRI for the demyelinating process seen in PML. The 
signal used in MT imaging alter the magnetization of the tissue - bound protons which in 
turn causes a decrease in the signal coming from the free protons, producing a change in 
signal intensity on the MR image. The result is expressed as the change in signal intensity 
compared to normal MR image and is called magnetization transfer ratio (MTR) .Studies( 
91,92) revealed that MTR in PML lesion is markedly reduced (22% to 26%) while in HIV 
encephalopathy has only mild reductions ( 38% to 40%), indicating that MT imaging could 
distinguish between them. Proton MR spectroscopy is another novel method which 
provides measurements of several neuromarkers, reflecting the neuronal viability. Only one 
study (93) compared the spectral changes in HIV encephalopathy with those in PML and 
found that the last one had a more profound decrease in NAA. 
Although CNS tuberculosis and neurosyphilis are not opportunistic infections per se, they 
are discussed in this chapter due to their protean manifestations.  
 
Fig. 5. PML: MRI (T2w FLAIR), sagital section: diffuse high signal changes in the subcortical 
white matter of the frontal, parietal and occipital lobes, suggesting U-fibres involvement, 
with no mass effect (INBI Matei Bals collection, courtesy of dr R. Ungurianu) 
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Fig. 6. PML: MRI (T2-w), transversal section: bilateral asymmetrical (predominantly on the 
right side) hyperintense signals in the subcortical white matter, just bellow the cortical 
ribbon (suggesting U-fibers involvement), without mass effect (INBI Matei Bals collection, 
courtesy of dr R. Ungurianu) 
  
Fig. 7. PML: MRI transversal section (T2-w): bilateral asymmetrical, predominantly on left 
side, hyperintense signals in the subcortical white matter, just bellow the cortical ribbon 
(suggesting U-fibers involvement); no displacement of nervous substance, normal ventricles 
(INBI Matei Bals collection, courtesy of dr. R. Ungurianu) 
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Tuberculosis involves CNS in several ways including meningitis, cerebral abscess, 
tuberculoma and stroke due to vasospasm and thrombosis. 
Besides typical presentations as meningitic syndrome, cases with atypical features are 
possible. Patients may present with a slowly progressive dementia characterized by 
personality changes, memory deficits and social withdrawal. Less common there is an 
encephalitic course manifested by seizures, stupor and coma.(94 ) 
The diagnosis relies on CSF analysis which typically reveals low glycorahia, elevated 
protein and a lymphocytic pleocytosis. Although CSF culture for acid fast bacilli is the gold 
standard for diagnosis, it takes 6-8 weeks to obtain a result and the sensitivity is low. PCR 
testing of the CSF is a rapid method for the detection of M.tuberculosis but the sensitivity is 
only 60% [95] 
Because CNS and pulmonary TB could have simultaneous onset, a chest radiograph may 
provide supportive evidence. 
 
Fig. 8. Tuberculous meningo-encephalitis. CT (with contrast medium): Important 
enhancement in the basal cistern and meninges, in posterior and middle fossa, (cisterna 
magna, cisterna pontis, cisterna ambiens and suprachiasmatic cistern) with mild 
enlargement of the ventricles. Moderate cerebral edema – poor delineation between white 
matter and grey matter, with blurred appearance of cerebral sulcus (INBI Matei Bals 
collection, courtesy of dr V Molagic) 
Neuroradiology plays an important role in diagnosis and the appearances take different 
forms: 
- intraparenchymal tuberculomas appears as multiple lesions less than 1 cm that 
predominate at the gray-white matter interface and periventricular region; the lesions 
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have little mass effect or edema (96).CT demonstrates the lesion poorly but shows the 
presence of basilar arachnoiditis, cerebral edema, infarction and the presence and 
course of hydrocephalus. On MRI , the aspect correlates with the evolutive phase: on 
T1W images the lesions are isointense to gray matter and may have a hyperintense rim; 
on T2W there is a hyperintensity and nodular enhancement for non-caseating 
granulomas. The lesions become hypointense on T2 with rim enhancement while 
caseation occurs. Healed tuberculomas may calcify or may progress to areas of 
encephalomalacia (97) 
- tuberculous abscesses are larger in size compared to tuberculomas, presenting as 
solitary loculated masses with mass effect and oedema; the ring enhancement is usually 
thin and uniform. They appear as hypodense lesion on CT and of high T2 signal on 
MRI.(98) 
- tuberculous meningitis – basilar meningitis is the most frequent form and is seen as 
leptomeningeal thickening and enhancement involving the basal cisterns, prepontine 
and ambient cisterns and suprasellar areas.(99). Hydrocephalus is a common finding 
and its association with basilar meningitis on CT and compatible clinical features is 
strongly suggestive of tuberculous meningitis.( 100,101) 
 
Fig. 9. Tuberculous meningo-encephalitis. CT (with contrast medium): Low-attenuating 
focal ischemic lesion in the fronto-parietal deep white matter in the proximity of right lateral 
ventricle (result from possible associated vasculitis) (INBI Matei Bals collection, courtesy of 
dr G Coltan) 
CMV encephalitis- CMV reactivation in HIV patients emerges bellow a 50 CD4 T 
cells/mmc level (as opportunistic infection) and can lead to ocular manifestations (retinitis, 
vitritis), neurological (encephalitis), pulmonary (pneumonitis), digestive apparatus 
involvement (esophageal ulcers and colitis); hepato-splenomegaly, lymph nodes 
enlargement and fever. The diagnosis presumes a positive serology (IgG positive; rarely 
IgM positive).  
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Serial fundoscopies are indicated when a HIV patient with a poor immunological status 
complains about visual problems – showing a typical ”cheese and ketchup” aspect of CMV 
retinitis. CMV viremia and blood pp65 antigen are positive. CMV PCR and pp65 antigen 
from CSF positive strengthen the diagnosis. Neuroimaging of CMV infection shows 
encephalitis (diffuse white matter impairment) and ventriculitis (ependymal enhancement).  
CMV IRIS could be very harmful, with subsequent lost of sight and emphasizing of 
neurological signs. 
Cerebral toxoplasmosis is an opportunistic parasitic infection in HIV infected patients, the 
most important neurological OI (opportunistic infections) in HAART era and it is due 
especially to a reactivation of a latent infection with Toxoplasma gondii. It appears bellow a 
level of 100 CD4 T cell/mmc with acute or subacute focal neurological deficits: paresis, 
sensory loss, aphasia; headache and a low degree of fever could be present; a chorioretinitis 
could accompany the neurological signs.  
The serology must be positive (IgG antibodies) for proving reactivation. A negative result 
makes toxoplasmosis unlikely. Very rare, IgM antibodies are present and demonstrate acute 
illness.  
The imaging exams are mandatory. MRI shows ring-enhancing mass(es) hyperintense 
lesions on T2W1/FLAIR, DWI; predilection for haemorrhages; decreased MR perfusion. 
There are solitary but typical multiple lesions.  
CSF analysis may be contributory if PCR for toxoplasma is positive. A negative result never 
rules out the diagnostic. 
 
Fig. 10. Cerebral toxoplasmosis. MRI (T1-w with contrast medium) transversal sections: 
nodular lesion with annular peripheral enhancement (hypersignal) and surrounding edema 
(hyposignal); could produces mass effect (INBI Matei Bals collection) 
A brain stereotactic biopsy can also be useful, especially when there is no clinical 
improvement in the first week of empirical antitoxoplasma treatment.  
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The fundoscopy is a necessary exam, especially for diagnose the association of a 
toxoplasmal chorioretinitis.  
Toxoplasmosis IRIS is very uncommon.  
 
Fig. 11. Cerebral toxoplasmosis. MRI (T2-w FLAIR) coronal sections: several lesions, some 
nodular and one irregular with hypersignal – same patient as above (INBI Matei Bals 
collection) 
Cryptococcosis is an opportunistic yeast infection with Cryptococcus neoformans, 
appearing lately during the HIV infection, below 100/mmc CD4 lymphocytes. It is an AIDS-
defining illness. The CNS involvement is the most frequent manifestation 
(meningoencephalitis, rare cryptococcoma), but it could be accompanied by pulmonary 
symptoms (dry cough and chest pain) and skin lesions (moluscum-like appearance). 
Patients complain mainly of headaches and confusion, progressing in days, then gait 
impairment and cranial nerves signs due to the high CSF pressure; fever and meningeal 
signs could be absent. The lumbar puncture sets the diagnosis by highlighting the fungus: 
direct visualization by native preparation or with India ink stain, presence of Cryptococcus 
antigen, CSF culture positive; CSF has usually high pressure, low number of cells and mild 
raising in protein level. Relatively frequent the blood cultures are positive. Blood 
Cryptococcus antigen is positive (titer>1/8).  
Imaging: The main manifestation, as a granulomatous meningitis has most often normal 
aspect on imaging exams, but a head CT scan or MRI are mandatory when there are even 
minimal neurological signs. There are some characteristic features in cryptococcal SNC 
infection: multiple T2 hyperintense small areas in basal ganglia, simetric nonenhancing 
cystic lesions - “gelatinous” pseudocysts within periventricular spaces, dilated Virchow-
Robin spaces, mild ventricular dilatation with nodular meningeal enhancement; vasculitis 
and infarctions. Cryptococcomas are very rare and appear as isolated or multiple solid ring 
enhancing masses preferentially in choroid plexus. 
In the course of IRIS, clinical signs are often atypical and characterized by extensive 
abscesses[8] 
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Fig. 12. Criptococcal meningitis (A) MRI (T2-w), transversal section: dilated Virchow-Robin 
spaces and mild ventricular dilatations; (B) MRI (T2-FLAIR), coronal section: hyperintense 
nodule and mild ventricular enlargement (INBI Matei Bals collection) 
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7.2 Neurosyphilis 
Defines the infection of the CNS by Treponema pallidum (T.pallidum) Because T. pallidum 
and HIV have the same route of transmission and different forms of neurosyphilis could 
have similar clinical features with HIV encephalopathy, it is worthwiling mentioning. 
Neurosyphilis can be classified into early forms (asymptomatic, symptomatic meningitis, 
meningovascular syphilis) and late forms (general paresis and tabes dorsalis). 
The early forms affect the meninges, CSF and vasculature while the late forms affect the 
brain and spinal cord.(102).Consequently, the clinical features for symptomatic meningitis 
consist in headache, nausea, vomiting and stiff neck associated with visual impairment ; 
for meningovascular syphilis the typical presentation is similar to an ischemic stroke with 
an acute or chronic onset in a young person. General paresis is a progressive dementia 
with deficits in memory and judgment and less often with psychiatric symptoms 
(depression, mania, psychosis ). Tabes dorsalis is characterized by ataxia and attacks of 
severe pain.  
There are described atypical forms of neurosyphilis, which mimic herpes encephalitis; the 
clinical presentation is dominated by cognitive changes with acute onset.(103) 
Serologic tests are represented by non treponemal tests - Venereal Disease Research 
Laboratory (VDRL) and Rapid Plasma Reagin ( RPR ) test and treponemal test-fluorescent 
treponemal antibody absorption ( FTA-ABS ) or T.pallidum agglutination assay ( TPPA ). 
Usually, these tests are reactive in all patients with early neurosyphilis. However, non 
treponemal tests could be nonreactive in late forms of neurosyphilis. In this situation, if the 
clinical suspicion is high, a treponemal test should be done; in case of a nonreactive test, 
there is no indication for further evaluation. If the test is reactive, a lumbar puncture should 
be performed. 
CSF examination is required for the diagnosis and should be done in every patient with 
compatible neurologic or ocular disease with known/unknown history of syphilis. CSF 
analysis reveals a lymphocytic pleocytosis (usually below 100 cells /microL), an elevated 
protein level and a reactive CSF VDRL, or a combination of these abnormalities. CSF VDRL 
is sensitive for the diagnosis but not specific. Therefore, in case of a negative CSF VDRL, a 
CSF-FTA-ABS should be performed.(104,105)  
Neuroimaging shows different modifications for each stage; 
- symptomatic meningitis –diffuse meningeal enhancement as well as enhancement of 
the CSF, cranial nerves and spinal root;-cerebral gummas appears as circumscribed 
masses with surrounding edema, located adjacent to the meninges and which extend 
into the cortex. On MRI , they are hypointense to isointense on T1W and hyperintense 
on T2W. 
- meningovascular syphilis- single or multiple areas of infarction 
- general paresis-cerebral atrophy 
- atypical form (herpes encephalitis like)- on MRI the lesions have high signal on T2 and 
fluid attenuated-inversion recovery (FLAIR) and are unilateral or bilateral in medial 
temporal areas (103) 
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Fig. 13. Neurosyphilis. MRI (T2-w FLAIR) coronal section: bilateral diffuse hyperintensity 
signal in frontal and temporal areas, involving the subcortical white matter (Floreasca 
Emergency Clinical Hospital courtesy of dr C Predescu) 
 
Fig. 14. Neurosyphilis MRI (T2-w) transversal section: bilateral hypointensity of the globus 
pallidus and putamen; disseminated temporal and insular high-signal lesions with 
subcortical topography (Floreasca Emergency Clinical Hospital, courtesy of dr C Predescu)  
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7.3 HAART neurotoxicity  
There is a wide spectrum of CNS complications in patients with HIV, ranging from 
psychiatric syndromes to seizures and cognitive impairment. In some cases, these 
neuropsychiatric complications could be related with the antiretroviral drugs, especially for 
those which penetrate the CNS. For the clinician, it is important to distinguish between 
symptoms related to CNS complications of HIV infection and side effects of HAART. 
The antiretrovirals most frequent associated with neuropsychiatric complications are 
nucleoside reverse transcriptase inhibitor ( NRTI ) and non nucleoside reverse transcriptase 
inhibitor ( NNRTI ). 
NRTI  
Zidovudine penetrate well the blood-brain barrier and therefore is a part of HAART 
regimens indicated for HAD. Moreover, Zidovudine has been found effective, at high doses, 
in slowing the progression of HAD . However, it was observed that up to 5% of patients 
who took Zidovudine for 1 year presented insomnia, agitation and confusion.(106) 
In the past, there where some reports of psychiatric symptoms such as mania and 
depression, associated with Zidovudine treatment. If the treatment was discontinued, the 
manic symptoms disappeared.(107). In recent years, fewer psychiatric problems were 
reported, partly because nowadays Zidovudine is used in lower doses (600mg/day) 
compared to those used in pre HAART era (2000mg/day). 
Other side effects reported were seizures, particularly in cases of overdose (108,109) 
NNRTI 
From this class of antiretrovirals, Efavirenz was the most frequent associated with CNS side 
effects including dizziness, headache, confusion, agitation, impaired concentration, 
amnesia,depersonalization, insomnia, hallucinations, abnormal or vivid dreams. These 
symptoms usually appear within the first month of treatment and decrease or even 
disappear spontaneously within 2 months. 
Psychiatric adverse events associated with Efavirenz are less frequent than neurological 
ones, consisting in anxiety, depression and suicidal ideation.(110,111) 
One of few studies investigating the neurotoxicity of Efavirenz on cognitive function 
showed that the treatment was associated with a higher risk of neurocognitive impairment, 
particularly on tasks requiring a higher attentional and executive load.(112) 
Clinicians should carefully watch for changes in behavior, cognition and mood in HIV 
patients treated with Efavirenz and should advise their patients regarding CNS effects of 
therapy. 
7.4 Neoplastic etiology 
Primary CNS lymphoma ( PCNSL ) is the second most common cause of intracranial mass 
after toxoplasmosis. There are many possible presenting symptoms depending on the 
location and extent of the tumor. In general, half of the patients present with focal 
neurological deficits ( seizures, aphasia, hemiparesis and localized weakness ) and the other 
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half present with non focal symptoms such as letharghy, headache, memory loss, altered 
mental status and personality changes. (113) 
Neuroimaging plays a crucial role in the positive and differential diagnosis and MRI is more 
sensitive than CT. 
MRI- typically, PCNSL lesions are solitary but in 50% of the cases multiple lesions could 
be seen; they are hypointense on both T1W and T2W imaging and the enhancement 
pattern is variable (homogeneous, heterogeneous or ring-like). PNCSL lesions can be 
located in the periventricular white matter, basal ganglia, corpus callosum and thalami. 
The most common location within the cerebral white matter is the frontal lobe followed 
by temporal, parietal and occipital lobes. Uncommon locations such as brain stem, cranial 
nerves, pineal gland and cavernous sinus are also encountered in AIDS patients. An 
important imaging characteristic which helps to differentiate PNCSL from toxoplasmosis 
is the tendency of extension toward the ependimal surface of the ventricular system.(98). 
PNCSL lesions often measure from 2 to 6 cm, have mass effect and are surrounded by 
perilesional edema. 
 
 
 
Fig. 15. Cerebral lymphoma: CT (with contrast medium), transverse section: solitary 
hyperintense lesion with annular enhancement and important perilesional edema with mass 
effect (A) at the diagnostic time and (B) after 4 months of treatment: important reduction of 
the lesion and remission of the mass effect (INBI Matei Bals and Fundeni Institute 
collections, courtesy of dr M Lazar) 
Thallium 201 (201T1) SPECT (single –photon emission CT) could be an important diagnostic 
tool. PNCSL lesions typically show increased uptake of 201T1 on SPECT imaging, in 
contrast to infectious and inflammatory lesions. This differentiating pattern of uptake 
becomes more evident on delayed scans (at 3-4h). 
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PET (positron emission tomography ) is useful for differential diagnosis because PNCSL 
lesions are more metabolically active than infectious lesions and take up F 18 
fludeoxyglucose (FDG) during PET. Moreover, metabolic uptake in PNCSL lesions may not 
be affected by prior corticosteroid use.(114) 
PCR detection of EBV DNA in CSF is limited by the risk of cerebral herniation in case of 
raised intracranial pressure. 
7.5 Reversible encephalopathies  
Complaints of cognitive impairment could be related to the coexistence of other medical 
conditions or substance abuse. Therefore, we should check for thyroid dysfunctions, anemia 
due to vitamin B12 deficiency, liver cirrhosis (portal encephalopathy), renal failure (uremia), 
infections (sepsis), intoxications ( alcoholism, recreational drugs). 
7.6 Immune reconstitution inflammatory syndrome (IRIS)  
A paradoxical clinical deterioration can occur in HIV patients shortly after HAART 
initiation and is due to an abrupt increase in immune surveillance which leads to pathologic 
inflammatory reactions. IRIS can be clinically expressed as an worsening of manifestations 
of underlying (known ) infection or an unmasking of a subclinical infection. Currently, there 
are no tested guidelines for the prevention or diagnosis of IRIS .Apart from clinical 
deterioration strictly related to HAART initiation, the diagnosis is suggested by a significant 
decrease in HIV RNA viral load and a rise in CD4 count.(17). 
IRIS may actually worsen PML initially but a clinical improvement is possible in time. On 
neuroimaging there is a contrast enhancement atypical for non inflammatory PML 
lesions.(115,116) 
8. Treatment  
HAART- consists of multiple antiretroviral drugs from different classes which stop HIV 
replication by acting in several key points of its life cycle. Besides suppression of viral 
replication, HAART reduces the appearance of resistance and restores immune function, 
increasing the CD4 count. 
ADJUVANT THERAPIES- consist of several small molecules which have been identified to 
possess anti-inflammatory and neuroprotective properties. 
The introduction of HAART since 1996 has led to major improvements in medical morbidity 
and life expectancy in HIV patients. The prevalence of opportunistic infections markedly 
decreased and the progression to AIDS was prevented or at least delayed. There were also 
registered significant improvement in neurological outcomes with a marked decrease in the 
incidence of HAD.(117,118) 
Pre-HAART era prevalence estimates were approximately 16% in AIDS cases (119), whereas 
more recent estimates are less than 5%.(3) 
However, HAART alone cannot eradicate HAND. Moreover, studies of HAND in treated 
patients showed high persisting rates of mild-to-moderate neurocognitive impairment (120), 
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suggesting that etiology of HAND could be multifactorial. Possible explanations for these 
observations are residual viral suppression in the CNS due to poor local penetration of some 
antiretroviral drugs, presence of drug-resistant viral strain and poor drug adherence. Other 
factors implicated are not HIV related and consist of possible neurotoxicity of antiretrovirals 
and coexisting illnesses such as cerebrovascular disease.( 3) 
Current recommendations on initiating or changing HAART are based on peripheral 
parameters such as CD4 count and plasma viral load and not on the status of infection in 
CNS. 
Although the optimal treatment for HAND has not been established, several studies have 
shown that antiretrovirals with good CNS penetration might positively affect cognition. 
Better penetration in the CNS, estimated by CPE score (CNS penetration effectiveness) is 
associated with a lower CSF viral load. (2,120). Based upon concentrations in CSF, drug 
properties and the results of clinical studies, each antiretroviral is assigned with a CPE score, 
ranging from 1 (low penetration) to 2 –3 (intermediate) and 4 (best 
penetration/effectivenesss). 
CPE score 1: Tenofovir, Zalcitabine, Nelfinavir, Ritonavir, Saquinavir/Ritonavir, Saquinavir, 
Tipranavir/Ritonavir, Enfuvirtide 
CPE score 2: Didanosine, Lamivudine, Stavudine, Etravirine, Atazanavir/Ritonavir, 
Atazanavir, Fosamprenavir; 
CPE score 3: Abacavir, Emtricitabine, Delavirdine, Efavirenz, Indinavir, 
Darunavir/Ritonavir, Fosamprenavir/Ritonavir, Lopinavir/Ritonavir, Maraviroc, 
Raltegravir 
CPE score 4: Zidovudine, Nevirapine, Indinavir/Ritonavir 
CPE rank is then calculated by adding up the scores for each antiretroviral drug in the 
regimen, according to CHARTER group score revised in 2010. (120) 
In contrast, there are studies that failed to identify an association between a high CPE score 
and a better cognitive outcome. (112,121) 
These controversial findings require further evaluation.  
For the moment, EACS guidelines (version 5-4) recommend that, for patients who are not on 
treatment, the clinician should consider initiation an antiretroviral regimen in which at least 
2 drugs penetrate CNS. Also for this category of patients, the risk for antiretroviral 
resistance should be considered ( if prior virological failure exists ).If the patient is already 
on treatment, changing the existing regimen with drugs which have better CNS penetration 
might be a solution. Whenever it is possible, genotyping of plasma and CSF HIV RNA 
should be done before changing the therapy. 
Regarding adjuvant therapies, exploratory trials have focused on probable mechanisms of 
neurologic pathology. One study tested minocycline, which may have anti-inflammatory, 
antioxidant and antiapoptotic effects(122). Sellegiline was another tested compound due to 
its ability to block apoptotic cell death in chronic HIV brain infection.(123) 
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9. Conclusion 
Despite HAART, cognitive impairment in HIV remains common. There are still unanswered 
questions regarding optimal timing and HAART regimen composition. Careful attention is 
needed to the treatment of cerebrovascular risk factors and co-morbidities. 
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